ARDX Ardelyx Inc.

-0.05  -1%
Previous Close 5.55
Open 5.50
Price To book 1.88
Market Cap 261819624
Shares 47,603,568
Volume 159,134
Short Ratio 5.34
Av. Daily Volume 295,928

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea. NDA filing due 2H 2018.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
  2. Ardelyx posts 4Q profit
  3. Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
  4. Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics — Fundamental Analysis, Key Performance Indications
  5. Ardelyx Announces Departure of Chief Scientific Officer
  6. Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
  7. Best NasdaqGM Growth Stocks
  8. 5 Great Breakout Stocks Offering Superlative Returns
  9. highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
  10. Can The Uptrend Continue for Ardelyx (ARDX)?
  11. Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?
  12. Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
  13. Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
  14. January Growth Stock Opportunities
  15. Why Ardelyx (ARDX) Could Beat Earnings Estimates Again
  16. Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
  17. featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
  18. 5 Affordable Breakout Stocks Offering Excellent Returns
  19. Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers